DEEP Launches a Platform to Build Digital Measures of Health
HELSINKI, Finland, July 30, 2024 /PRNewswire/ -- DEEP Measures announces its collaborative platform to build digital measures in clinical trials,...
Pharmaceutical
CSafe launches reusable Silverpod pallet shipper to help pharma companies save on disposal costs and hit sustainability targets
New pallet improves cost and operational efficiency while reducing environmental impact; includes real-time visibility with cloud connectivity Key features include:...
Datavant, Premier Inc, Privacy Analytics to Showcase Privacy Enhancing Technologies in Healthcare at Congressional Briefing
NEW YORK, July 29, 2024 /PRNewswire/ -- Datavant, the leading health data platform company, is proud to announce its participation in...
Prescription Digital Therapeutics (PDT) Market Expected to Grow at a CAGR of 22.41% from 2024 to 2031 | Exclusive Report by InsightAce Analytic Pvt. Ltd
JERSEY CITY, N.J., July 29, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report...
New Research Supports PillSafe’s Methodology in Reducing the Risk of Medication Misuse and Overuse
The study raises concerns that overprescribing medications and the resulting unused medication are drivers of opioid misuse.EDMOND, OK / ACCESSWIRE...
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its...
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its...
Parexel Releases 2023 Environmental, Social and Governance Report
DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the...
Veru to Participate in the BTIG Virtual Biotechnology Conference
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis...
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory...
Hummingbird Bioscience Announces Key Leadership Appointments
Kon Yew Kwek, BM BCh, DPhil, appointed Chief Medical Officer Lisa Ooi, PhD, appointed Chief Operating Officer SAN FRANCISCO and...
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
SEATTLE and VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
The Phase 2 trial of VTX958 in Crohn’s disease did not meet its primary endpoint of change from baseline in...
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at day...
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET FLORHAM PARK, N.J., July 29, 2024...
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on...
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practicesProvides access to a large portion of...
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially availableProvides rapid clearance of atopic dermatitis signs and symptoms and significant...